A CHRNA5 smoking risk variant decreases the aversive effects of nicotine in humans

Neuropsychopharmacology

Volumn 40, Issue 12, 2015, Pages 2813-2821

  Jensen, Kevin P ^a,b   Devito, Elise E ^a,b   Herman, Aryeh I ^a,b   Valentine, Gerald W ^a,b   Gelernter, Joel ^a,b   Sofuoglu, Mehmet ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; SODIUM CHLORIDE; CHRNA5 PROTEIN, HUMAN; COTININE; HYDROXYCOTININE; NERVE PROTEIN; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ADULT; AFRICAN AMERICAN; ARTICLE; AVERSION; CARDIOVASCULAR RESPONSE; CHRNA5 GENE; COGNITION; EUROPEAN AMERICAN; EXECUTIVE FUNCTION; FEMALE; GENE; GENE CLUSTER; GENETIC VARIABILITY; GENOTYPE; HEART RATE; HOMOZYGOTE; HUMAN; MALE; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED; COGNITION DISORDERS; DRUG EFFECTS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PSYCHOLOGY; QUESTIONNAIRE; SINGLE NUCLEOTIDE POLYMORPHISM; WITHDRAWAL SYNDROME;

ADULT; BLOOD PRESSURE; COGNITION DISORDERS; COTININE; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HEART RATE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROPSYCHOLOGICAL TESTS; NICOTINE; NICOTINIC AGONISTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, NICOTINIC; SMOKING; SUBSTANCE WITHDRAWAL SYNDROME; SURVEYS AND QUESTIONNAIRES;

EID: 84944356487     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.131     Document Type: Article

References (64)

1. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T et al (2008). Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25. 1. Nat Genet 40: 616-622.
2. Bailey CD, De Biasi M, Fletcher PJ, Lambe EK (2010). The nicotinic acetylcholine receptor alpha5 subunit plays a key role in attention circuitry and accuracy. J Neurosci 30: 9241-9252.
3. Baker TB, Weiss RB, Bolt D, von Niederhausern A, Fiore MC, Dunn DM et al (2009). Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine Tob Res 11: 785-796.
4. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV et al (2013). Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics 23: 94-103.
5. Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H et al (2008). Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry 13: 368-373.
6. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF et al (2007). Novel genes identified in a highdensity genome wide association study for nicotine dependence. Hum Mol Genet 16: 24-35.
7. Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X et al (2008). Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 165: 1163-1171.
8. Chen LS, Saccone NL, Culverhouse RC, Bracci PM, Chen CH, Dueker N et al (2012). Smoking and genetic risk variation across populations of European, Asian, and African American ancestry- a meta-analysis of chromosome 15q25. Genet Epidemiol 36: 340-351.
9. Chen X, Chen J, Williamson VS, An SS, Hettema JM, Aggen SH et al (2009). Variants in nicotinic acetylcholine receptors alpha5 and alpha3 increase risks to nicotine dependence. Am J Med Genet B Neuropsychiatr Genet 150B: 926-933.
10. Dempsey D, Tutka P, Jacob P, Allen F, Schoedel K, Tyndale RF et al (2004). Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76: 64-72.
11. DeVito EE, Herman AI, Waters AJ, Valentine GW, Sofuoglu M (2013). Subjective, physiological, and cognitive responses to intravenous nicotine: effects of sex and menstrual cycle phase. Neuropsychopharmacology 39: 1431-1440.
12. Evans DE, MacQueen DA, Jentink KG, Park JY, Lin HY, Drobes DJ (2014). CHRNA5 variants moderate the effect of nicotine deprivation on a neural index of cognitive control. Genes Brain Behav 13: 626-632.
13. First MB, Spitzer RL, Gibbon M, Williams JB (1996). Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. Biometrics Research Department, New York State Psychiatric Institution: New York.
14. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ (2011). Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature 471: 597-601.
15. Fowler CD, Tuesta L, Kenny PJ (2013). Role of alpha5 nicotinic acetylcholine receptors in the effects of acute and chronic nicotine treatment on brain reward function in mice. Psychopharmacology (Berl) 229: 503-513.
16. Frahm S, Slimak MA, Ferrarese L, Santos-Torres J, Antolin-Fontes B, Auer S et al (2011). Aversion to nicotine is regulated by the balanced activity of beta4 and alpha5 nicotinic receptor subunits in the medial habenula. Neuron 70: 522-535.
17. Freathy RM, Ring SM, Shields B, Galobardes B, Knight B, Weedon MN et al (2009). A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5- CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum Mol Genet 18: 2922-2927.
18. Gelernter J KH, Sherva R, Almasy L, Herman AI, Koesterer R, Zhao H et al (2015). Genomewide association study of nicotine dependence in American populations: identification of novel risk loci in both African- and European-Americans. Biol Psychiatry 77: 493-503.
19. Hansen HM, Xiao Y, Rice T, Bracci PM, Wrensch MR, Sison JD et al (2010). Fine mapping of chromosome 15q25. 1 lung cancer susceptibility in African-Americans. Hum Mol Genet 19: 3652-3661.
20. Hatsukami DK, Benowitz NL, Rennard SI, Oncken C, Hecht SS (2006). Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 8: 169-191.
21. Herman AI, Jatlow PI, Gelernter J, Listman JB, Sofuoglu M (2013). COMT Val158Met modulates subjective responses to intravenous nicotine and cognitive performance in abstinent smokers. Pharmacogenomics J 13: 490-497.
22. Hoffmann D, Wynder EL (1986). Chemical constituents and bioactivity of tobacco smoke. IARC Sci Publ 74: 145-165.
23. Hong LE, Hodgkinson CA, Yang YH, Sampath H, Ross TJ, Buchholz B et al (2010). A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction. Proc Natl Acad Sci USA 107: 13509-13514.
24. Hughes JR, Hatsukami D (1986). Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43: 289-294.
25. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D et al (2008). A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452: 633-637.
26. Jackson KJ, Marks MJ, Vann RE, Chen X, Gamage TF, Warner JA et al (2010). Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice. J Pharmacol Exp Ther 334: 137-146.
27. Jensen KP, Herman AI, Morean ME, Kranzler HR, Gelernter J, Sofuoglu M et al (2014). FKBP5 variation is associated with the acute and chronic effects of nicotine. Pharmacogenomics J (e-pub ahead of print 23 December 2014; doi:10. 1038/tpj. 2014. 76).
28. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN et al (2013). 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 368: 341-350.
29. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV et al (2012). Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 37: 641-650.
30. Kuryatov A, Berrettini W, Lindstrom J (2011). Acetylcholine receptor (AChR) alpha5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (alpha4beta2)(2) alpha5 AChR function. Mol Pharmacol 79: 119-125.
31. Lerman C, Gu H, Loughead J, Ruparel K, Yang Y, Stein EA (2014). Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function. JAMA Psychiatry 71: 523-530.
32. Li MD, Cheng R, Ma JZ, Swan GE (2003). A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 98: 23-31.
33. Li MD, Yoon D, Lee JY, Han BG, Niu T, Payne TJ et al (2010). Associations of variants in CHRNA5/A3/B4 gene cluster with smoking behaviors in a Korean population. PLoS One 5: e12183.
34. Lips EH, Gaborieau V, McKay JD, Chabrier A, Hung RJ, Boffetta P et al (2010). Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. Int J Epidemiol 39: 563-577.
35. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L et al (2010). Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet 42: 436-440.
36. Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O'Malley SS (2013). The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology (Berl) 227: 177-192.
37. Morel C, Fattore L, Pons S, Hay YA, Marti F, Lambolez B et al (2014). Nicotine consumption is regulated by a human polymorphism in dopamine neurons. Mol Psychiatry 19: 930-936.
38. Munafo MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P (2011). CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res 13: 982-988.
39. Newhouse PA, Potter A, Singh A (2004). Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 4: 36-46.
40. Perez-Stable EJ, Herrera B, Jacob P 3rd, Benowitz NL (1998). Nicotine metabolism and intake in black and white smokers. JAMA 280: 152-156.
41. Perkins KA (1996). Sex differences in nicotine versus nonnicotine reinforcement as determinants of tobacco smoking. Exp Clin Psychopharm 4: 166-177.
42. Reeves DL, Winter KP, Bleiberg J, Kane RL (2007). ANAM (R) genogram: historical perspectives, description, and current endeavors. Arch Clin Neuropsych 22: S15-S37.
43. Saccone NL, Culverhouse RC, Schwantes-An TH, Cannon DS, Chen X, Cichon S et al (2010). Multiple independent loci at chromosome 15q25. 1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet 6: 8.
44. Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA et al (2007). Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet 16: 36-49.
45. Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF et al (2011). Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 156B: 275-284.
46. Schneider NG, Terrace S, Koury MA, Patel S, Vaghaiwalla B, Pendergrass R et al (2005). Comparison of three nicotine treatments: initial reactions and preferences with guided use. Psychopharmacology (Berl) 182: 545-550.
47. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF (2004). Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14: 615-626.
48. Schuh KJ, Schuh LM, Henningfield JE, Stitzer ML (1997). Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology (Berl) 130: 352-361.
49. Sherva R, Kranzler HR, Yu Y, Logue MW, Poling J, Arias AJ et al (2010). Variation in nicotinic acetylcholine receptor genes is associated with multiple substance dependence phenotypes. Neuropsychopharmacology 35: 1921-1931.
50. Sofuoglu M, Babb D, Hatsukami DK (2003). Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers. Nicotine Tob Res 5: 947-953.
51. Sofuoglu M, Herman AI, Nadim H, Jatlow P (2012). Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. Neuropsychopharmacology 37: 1509-1516.
52. Sofuoglu M, Mouratidis M, Yoo S, Culligan K, Kosten T (2005). Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 181: 504-510.
53. Sofuoglu M, Poling J, Mouratidis M, Kosten T (2006). Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 184: 645-651.
54. Sofuoglu M, Yoo S, Hill KP, Mooney M (2008). Self-administration of intravenous nicotine in male and female cigarette smokers. Neuropsychopharmacology 33: 715-720.
55. Spitz MR, Amos CI, Dong Q, Lin J, Wu X (2008). The CHRNA5-A3 region on chromosome 15q24-25. 1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst 100: 1552-1556.
56. Tammimaki A, Herder P, Li P, Esch C, Laughlin JR, Akk G et al (2012). Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by alpha3beta4alpha5 nicotinic acetylcholine receptors. Neuropharmacology 63: 1002-1011.
57. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP et al (2008). A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452: 638-642.
58. Tiffany ST, Drobes DJ (1991). The development and initial validation of a questionnaire on smoking urges. Br J Addict 86: 1467-1476.
59. Tobacco and Genetics Consortium (2010). Genome-wide metaanalyses identify multiple loci associated with smoking behavior. Nat Genet 42: 441-447.
60. Tyndale RF, Pianezza ML, Sellers EM (1999). A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. Nicotine Tob Res 1(Suppl 2): S63-S67; discussion S69-70.
61. Tyndale RF, Sellers EM (2002). Genetic variation in CYP2A6- mediated nicotine metabolism alters smoking behavior. Ther Drug Monit 24: 163-171.
62. Wang JC, Cruchaga C, Saccone NL, Bertelsen S, Liu P, Budde JP et al (2009). Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. Hum Mol Genet 18: 3125-3135.
63. Watson D, Clark LA, Tellegen A (1988). Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54: 1063-1070.
64. Yang BZ, Zhao H, Kranzler HR, Gelernter J (2005). Practical population group assignment with selected informative markers: characteristics and properties of Bayesian clustering via STRUCTURE. Genet Epidemiol 28: 302-312.